This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Parke, A. Articles by Rothfield, N. Search for Related Content PubMed PubMed Citation Articles by Parke, A. Articles by Rothfield, N. Social Bookmarking                         What's this?

Antimalarial drugs in pregnancy — the North American experience

The University of Connecticut Health Center, Farmington Avenue, Farmington, CT 06030, USA

NF Rothfield

The University of Connecticut Health Center, Farmington Avenue, Farmington, CT 06030, USA

The use of the 4-aminoquinoline antimalarials in pregnancy is controversial. The current practice of discontinuing these medications because of pregnancy makes little sense as the half-life of these medications is so long. Patients with SLE have increased fetal wastage and one of the factors known to contribute to this fetal wastage is disease activity. It is also known that discontinuing the 4-aminoquinoline antimalarial drugs can precipitate flares of disease in lupus patients. Mothers and their potential offspring are therefore at risk for flares of disease and pregnancy failure if these medications are discontinued because of pregnancy. This review addresses the North American experience of the use of antimalarial drugs in pregnant lupus patients. Unlike most centers in North America, we continue our patients on these medications throughout pregnancy and to date have documented 16 lupus patients who have taken these drugs throughout pregnancy. Our most recent study docu ments nine pregnancies in eight women. All of these pregnancies resulted in live births (five pre-term deliveries and four full-term deliveries). There were no congenital abnormalities in these infants and follow-up to date has revealed no evidence of ocular or oral deficits in any of these children. One patient experienced a flare of disease when her antimalarial therapy was temporarily discontinued.

Key Words: antimalarial drugs • hydroxychloroquine (plaquenil) • chloroquine • pregnancy

Lupus, Vol. 5, No. 1 suppl, S67-S69 (1996)
DOI: 10.1177/096120339600500115


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. C. T. Kong Pregnancy of a lupus patient--a challenge to the nephrologist Nephrol. Dial. Transplant., February 1, 2006; 21(2): 268 - 272. [Full Text] [PDF]

				R A Levy, V S Vilela, M J Cataldo, R C Ramos, J L. Duarte, B R Tura, E M. Albuquerque, and N R Jesus Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study Lupus, June 1, 2001; 10(6): 401 - 404. [Abstract] [PDF]

				J. P Buyon, K. C Kalunian, R. Ramsey-Goldman, M. A Petri, M. D Lockshin, G. Ruiz-Irastorza, and M. Khamashta Assessing disease activity in SLE patients during pregnancy Lupus, October 1, 1999; 8(8): 677 - 684. [PDF]